Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$287.0K-84.43%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen H. Willard
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Beta
- -0.26
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -16.43
Financials
Revenue
$287.0K-84.4%Net Income
$-6.07MEBITDA
$-6.27MFree Cash Flow
$-5.76M-3511.3%EPS (diluted)
$-1.90Shares Outstanding (diluted)
3.14M+1859.0%Operating Expenses
$6.35MCash & Debt
$10.08MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.20M | $-22.70M | $-12.90 |
| 2024 | $2.39M | $-15.97M | $-10.70 |
| 2023 | $709.0K | $-21.41M | $-102.20 |
| 2022 | $1.22M | $-18.84M | $-90.00 |
| 2021 | $1.31M | $-17.05M | $-90.00 |
| 2020 | $5.63M | $-3.72M | $-22.10 |
| 2019 | $5.63M | $-3.72M | $-18.70 |
| 2018 | $2.13M | $-6.34M | $-39.80 |
Valuation
LGVNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-7.69%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·5d ago·Positive
Longeveron to Participate in Three Longevity/Aging Investment Conferences MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.
View source ↗ - Newsreuters.com·19d ago·Positive
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition Longeveron on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.
View source ↗ - Newsglobenewswire.com·19d ago·Positive
…mizing cost containment and will explore all options with the goal of maximizing shareholder value MIAMI, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestrocel as an adjunct to Stage 2 palliative surgery i…
View source ↗ - Newsglobenewswire.com·33d ago·Positive
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference Longeveron to present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026; presentation 9/14/26 at 1:00pm ET
View source ↗ - Newsglobenewswire.com·42d ago·Positive
Longeveron Announces 1-for-10 Reverse Stock Split MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company's Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “20…
View source ↗ - Newsglobenewswire.com·47d ago·Positive
…ce, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company's executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer…
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-1.95 per share
Typical surprise +85.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-1.90 vs $-1.75miss
- Wed, May 13$-0.19 vs $-1.80beat
- Tue, Mar 17$-2.30 vs $-4.20beat
- Tue, Nov 4$-0.39 vs $-2.60beat
- Wed, Aug 13$-0.33 vs $-0.35beat
- Thu, May 8$-0.34 vs $-3.40beat
Estimates and results for LGVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LGVN officers and directors.
- Bought
- $50k
- Sold
- $37k
4 trades
4 trades
- Locklear Lisabought
- Locklear Lisabought
- Baluch Khosobought
- Baluch Khosobought
- Soffer Rocksold
- Soffer Rocksold
- Soffer Rocksold
- Hare Joshuasold
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LGVN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.